Document is current
Any future updates will be listed below
-
Authors
Hayashino, Yasuaki
Tsuboi, Satoshi
Yamamoto, Yuiko
Ishii, Hitoshi
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 27 August 2024
Accepted: 15 October 2024
First Online: 1 November 2024
Declarations
:
: Yasuaki Hayashino reports personal fees from Boehringer Ingelheim, Daiichi Sankyo Company Ltd, Eli Lilly Japan K.K., Kowa Pharmaceuticals Inc., Merck & Co. Inc., Novo Nordisk Pharma Ltd, Ono Pharmaceutical Co. Ltd, Sanofi K.K., Sumitomo Pharma Co. Ltd and Takeda Pharmaceutical Company Ltd, outside of the submitted work. Satoshi Tsuboi and Yuiko Yamamoto are employees and shareholders of Novo Nordisk Pharma Ltd. Hitoshi Ishii received payment or honoraria for lectures from Eli Lilly Japan K.K., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Japan Pharma Ltd, Sanofi K.K. and Sumitomo Pharma Co. Ltd.
: This study was conducted in accordance with the principles outlined in the Declaration of Helsinki, which were consistent with good clinical practices and applicable laws and regulations in Japan. The study protocol and informed consent form were submitted to the Medical Corporation TOUKEIKAI Kitamachi Clinic Ethical Review Board for review/approval as a minimal-risk study, and ethical approval was granted on May 17, 2023 (NN1436-7732). Before completing the survey, all respondents provided informed consent for participation and publication of aggregated level data via a web-based platform.
